Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
Year: 2009
Type: article
Abstract: lasma LDL cholesterol level is a major determinant of cardiovascular disease (CVD) risk.The striking results of the early large-scale statin trials showed that LDL levels can be reduced by 30-40% with comparable percentage reductions in CVD risk.More recent trials show that there is progressively greater relative risk reduction as the on-treatment level of LDL drops.In the JUPITER trial (1), rosuvastatin treatment of healthy subjects who had elevated CRP levels lowered LDL cholesterol levels Ϸ50% [from a baseline median of 108 mg/dL to 55 mg/dL (25% had values Ͻ44 mg/ dL)] and resulted in a Ϸ50% reduction in all CVD events.We recently suggested that an ''ideal'' LDL cholesterol level of 50 mg/dL should be the target goal of therapy in all high-risk subjects (2), but the Jupiter trial extends this concept to an even larger population and supports the concept that ''the lower the LDL the better'' is a reasonable position.However, achieving LDL levels of 50 mg/dL or even lower in patients with high initial values is often not possible with statins alone, even with maximum dosages.Such patients often require 2 or even 3 different drugs to reach a LDL level Ͻ100 mg/dL, much less 50 mg/dL, and such combinations increase the risk of side effects.Consequently, the search for new cholesterol-lowering interventions continues apace.In this issue of PNAS, Chan et al. (3) describe dramatic cholesterol lowering in nonhuman primates with the use of a mAb against proprotein convertase subtilisin/ kexin type 9 (PCSK9), a recently described key regulator of hepatocyte LDL receptor (LDL-R) expression.
Authors: Daniel Steinberg, Joseph L. Witztum
Institution: University of California San Diego
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2028004589
